董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rajeev Shah | 男 | Director | 42 | 未披露 | 未持股 | 2019-08-16 |
| Ken Takanashi | 男 | Director | 55 | 未披露 | 未持股 | 2019-08-16 |
| Thomas King | 男 | Director | 64 | 4.17万美元 | 未持股 | 2019-08-16 |
| Michael Riebe | 男 | Director | 59 | 3.34万美元 | 未持股 | 2019-08-16 |
| Elisabeth Sandoval Little | 女 | Director | 57 | 未披露 | 未持股 | 2019-08-16 |
| John A. Kollins | 男 | Director, President and Chief Executive Officer | 56 | 56.82万美元 | 未持股 | 2019-08-16 |
| Heath Lukatch | 男 | Chairman of the Board of Director | 52 | 未披露 | 未持股 | 2019-08-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Detlef Albrecht | 男 | Chief Medical Officer | 58 | 47.62万美元 | 未持股 | 2019-08-16 |
| Tom O'Neil | 男 | Chief Financial Officer | 54 | 未披露 | 未持股 | 2019-08-16 |
| Mic Iwashima | 男 | Vice President and Head of Operations | 41 | 未披露 | 未持股 | 2019-08-16 |
| Robert Schultz | 男 | Vice President and Head of CMC | 55 | 未披露 | 未持股 | 2019-08-16 |
| Shannon Strom | 女 | Vice President and Head of Regulatory Affairs | 43 | 未披露 | 未持股 | 2019-08-16 |
| John A. Kollins | 男 | Director, President and Chief Executive Officer | 56 | 56.82万美元 | 未持股 | 2019-08-16 |
董事简历
中英对照 | 中文 | 英文- Rajeev Shah
-
Rajeev Shah，2013年9月以来，他一直担任我们董事会的成员。他是RA Capital Management公司（一个投资咨询公司，一直在投资于卫生保健公司）的合伙人和投资组合经理（2002年以来）。2004年加入RA Capital公司之前，他曾担任Altus Pharmaceuticals公司的高级项目负责人。他持有Cornell University的化学学士学位。
Rajeev Shah has served as a member of our Board of Directors since March 2017. Mr. Shah has been a managing partner at RA Capital Management, L.P., a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics, since 2004. Mr. Shah is also a member of the board of directors of Eidos Therapeutics, Inc., Kala Pharmaceuticals, Inc., Satsuma Pharmaceuticals, Inc.,. and Black Diamond Therapeutics, Inc., each a public biopharmaceutical company. Mr. Shah was previously a member of the board of directors of KalVista Pharmaceuticals, Inc. from June 2015 through April 2018 and Ra Pharmaceuticals, Inc. from July 2015 through April 2020 both public pharmaceutical companies. Mr. Shah received a B.A. in Chemistry from Cornell University. - Rajeev Shah，2013年9月以来，他一直担任我们董事会的成员。他是RA Capital Management公司（一个投资咨询公司，一直在投资于卫生保健公司）的合伙人和投资组合经理（2002年以来）。2004年加入RA Capital公司之前，他曾担任Altus Pharmaceuticals公司的高级项目负责人。他持有Cornell University的化学学士学位。
- Rajeev Shah has served as a member of our Board of Directors since March 2017. Mr. Shah has been a managing partner at RA Capital Management, L.P., a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics, since 2004. Mr. Shah is also a member of the board of directors of Eidos Therapeutics, Inc., Kala Pharmaceuticals, Inc., Satsuma Pharmaceuticals, Inc.,. and Black Diamond Therapeutics, Inc., each a public biopharmaceutical company. Mr. Shah was previously a member of the board of directors of KalVista Pharmaceuticals, Inc. from June 2015 through April 2018 and Ra Pharmaceuticals, Inc. from July 2015 through April 2020 both public pharmaceutical companies. Mr. Shah received a B.A. in Chemistry from Cornell University.
- Ken Takanashi
-
Ken Takanashi，自2012年7月在公司董事会工作。2002年Takanashi先生担任Shin Nippon Biomedical Laboratories Ltd.（SNBL）和子公司的不同的执行管理和董事职位，目前担任监督业务部门高级管理董事。Takanashi先生担任SNBL USA, Ltd.（Shin Nippon Biomedical Laboratories的子公司）的财务总监（2012-2014年）。他拥有华威大学（University of Warwick）工商管理硕士学位和东京大学（University of Tokyo）学士学位，他也是一名注册会计师。
Ken Takanashi,has served as a director since July 2012. Since 2002, Mr. Takanashi has served in various executive management and director roles at Shin Nippon Biomedical Laboratories Ltd. ("SNBL") and its affiliates and currently serves as its Executive Vice President, Representative Director. Mr. Takanashi was the Chief Financial Officer of SNBL USA, Ltd., a subsidiary of Shin Nippon Biomedical Laboratories, from 2012 to 2014. Since 2016, Mr. Takanashi has also served on the board of directors of Satsuma Pharmaceuticals, Inc., a biopharmaceutical company that was previously publicly-traded and became a privately-held company and wholly-owned subsidiary of SNBL on June 8, 2023. Mr. Takanashi also serves as a member of the board of directors of TMS Co., Ltd., a biopharmaceutical company listed on the Tokyo Stock Exchange, since March 2022. Mr. Takanashi earned an M.B.A. from the University of Warwick and received his bachelor's degree from the University of Tokyo and is a Chartered Public Accountant. - Ken Takanashi，自2012年7月在公司董事会工作。2002年Takanashi先生担任Shin Nippon Biomedical Laboratories Ltd.（SNBL）和子公司的不同的执行管理和董事职位，目前担任监督业务部门高级管理董事。Takanashi先生担任SNBL USA, Ltd.（Shin Nippon Biomedical Laboratories的子公司）的财务总监（2012-2014年）。他拥有华威大学（University of Warwick）工商管理硕士学位和东京大学（University of Tokyo）学士学位，他也是一名注册会计师。
- Ken Takanashi,has served as a director since July 2012. Since 2002, Mr. Takanashi has served in various executive management and director roles at Shin Nippon Biomedical Laboratories Ltd. ("SNBL") and its affiliates and currently serves as its Executive Vice President, Representative Director. Mr. Takanashi was the Chief Financial Officer of SNBL USA, Ltd., a subsidiary of Shin Nippon Biomedical Laboratories, from 2012 to 2014. Since 2016, Mr. Takanashi has also served on the board of directors of Satsuma Pharmaceuticals, Inc., a biopharmaceutical company that was previously publicly-traded and became a privately-held company and wholly-owned subsidiary of SNBL on June 8, 2023. Mr. Takanashi also serves as a member of the board of directors of TMS Co., Ltd., a biopharmaceutical company listed on the Tokyo Stock Exchange, since March 2022. Mr. Takanashi earned an M.B.A. from the University of Warwick and received his bachelor's degree from the University of Tokyo and is a Chartered Public Accountant.
- Thomas King
-
Thomas King自2017年9月以来一直担任我们的董事会成员。King先生目前还担任Vivus，Inc.公司（一家公共制药公司）的董事会成员。此前，金先生于2017年5月至2018年5月在Vivus，Inc.担任过各种职务，包括临时首席执行官，临时总裁以及独立生物技术顾问和顾问。此前，金先生于2003年6月至2016年8月担任AlexzaPharmaceuticals，Inc.（一家公开上市的制药公司）的总裁，首席执行官兼董事会成员。2015年10月至2016年8月，金先生还担任AlexzaPharmaceuticals，Inc.首席财务官兼首席会计官King从2002年9月到2003年4月担任Cognetix，Inc.（一家私人生物制药开发阶段公司）总裁、首席执行官和董事会成员。King从1994年1月到2001年2月在Anesta Corporation（一家上市制药公司）担任多个高级执行职位，包括1995年1月至1997年1月担任总裁兼首席运营官，1997年1月至2000年10月担任总裁兼首席执行官，并从1995年1月起担任董事会成员，直到该公司被上市生物制药公司Cephalon，Inc.收购。King先生目前担任Concentric Angenesics，Inc.和Faraday Pharmaceuticals，Inc.的董事会成员，这两家公司都是私人持有的生物技术公司。King先生还担任Spire BioVentures的导师，该公司是一家协助生物技术企业家的多学科国际财团，并担任科罗拉多大学生物前沿研究所（University of Colorado BioFrontiers Institute）的顾问委员会成员。King先生在麦克弗森学院（McPherson College）获得化学学士学位，并在堪萨斯大学商学院（University of Kansas Graduate School of Business）获得工商管理硕士学位。
Thomas King has served as a member of our board of directors since September 2017. Mr. King also currently serves on the board of directors of VIVUS, Inc. a public pharmaceutical company. Previously, Mr. King served in various roles at VIVUS, Inc. from May 2017 to May 2018 including as the interim Chief Executive Officer, as interim President, and as an independent biotechnology consultant and advisor. Previously, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Alexza Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from June 2003 to August 2016. From October 2015 to August 2016 Mr. King also served as Chief Financial Officer and Chief Accounting Officer of Alexza Pharmaceuticals, Inc. From September 2002 to April 2003 Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a privately held biopharmaceutical development stage company. From January 1994 to February 2001 Mr. King held various senior executive positions at Anesta Corporation, a publicly traded pharmaceutical company, including President and Chief Operating Officer from January 1995 to January 1997 and President and Chief Executive Officer from January 1997 to October 2000 and was a member of the board of directors from January 1995 until it was acquired by Cephalon, Inc., a publicly traded biopharmaceutical company. Mr. King currently serves on the board of directors of Concentric Analgesics, Inc. and Faraday Pharmaceuticals, Inc., both privately held biotechnology companies. Mr. King also serves as a mentor at SPIRE Bioventures, a multi-disciplinary international consortium aiding biotechnology entrepreneurs, and as an Advisory Board Member of the University of Colorado BioFrontiers Institute. Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business. - Thomas King自2017年9月以来一直担任我们的董事会成员。King先生目前还担任Vivus，Inc.公司（一家公共制药公司）的董事会成员。此前，金先生于2017年5月至2018年5月在Vivus，Inc.担任过各种职务，包括临时首席执行官，临时总裁以及独立生物技术顾问和顾问。此前，金先生于2003年6月至2016年8月担任AlexzaPharmaceuticals，Inc.（一家公开上市的制药公司）的总裁，首席执行官兼董事会成员。2015年10月至2016年8月，金先生还担任AlexzaPharmaceuticals，Inc.首席财务官兼首席会计官King从2002年9月到2003年4月担任Cognetix，Inc.（一家私人生物制药开发阶段公司）总裁、首席执行官和董事会成员。King从1994年1月到2001年2月在Anesta Corporation（一家上市制药公司）担任多个高级执行职位，包括1995年1月至1997年1月担任总裁兼首席运营官，1997年1月至2000年10月担任总裁兼首席执行官，并从1995年1月起担任董事会成员，直到该公司被上市生物制药公司Cephalon，Inc.收购。King先生目前担任Concentric Angenesics，Inc.和Faraday Pharmaceuticals，Inc.的董事会成员，这两家公司都是私人持有的生物技术公司。King先生还担任Spire BioVentures的导师，该公司是一家协助生物技术企业家的多学科国际财团，并担任科罗拉多大学生物前沿研究所（University of Colorado BioFrontiers Institute）的顾问委员会成员。King先生在麦克弗森学院（McPherson College）获得化学学士学位，并在堪萨斯大学商学院（University of Kansas Graduate School of Business）获得工商管理硕士学位。
- Thomas King has served as a member of our board of directors since September 2017. Mr. King also currently serves on the board of directors of VIVUS, Inc. a public pharmaceutical company. Previously, Mr. King served in various roles at VIVUS, Inc. from May 2017 to May 2018 including as the interim Chief Executive Officer, as interim President, and as an independent biotechnology consultant and advisor. Previously, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Alexza Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from June 2003 to August 2016. From October 2015 to August 2016 Mr. King also served as Chief Financial Officer and Chief Accounting Officer of Alexza Pharmaceuticals, Inc. From September 2002 to April 2003 Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a privately held biopharmaceutical development stage company. From January 1994 to February 2001 Mr. King held various senior executive positions at Anesta Corporation, a publicly traded pharmaceutical company, including President and Chief Operating Officer from January 1995 to January 1997 and President and Chief Executive Officer from January 1997 to October 2000 and was a member of the board of directors from January 1995 until it was acquired by Cephalon, Inc., a publicly traded biopharmaceutical company. Mr. King currently serves on the board of directors of Concentric Analgesics, Inc. and Faraday Pharmaceuticals, Inc., both privately held biotechnology companies. Mr. King also serves as a mentor at SPIRE Bioventures, a multi-disciplinary international consortium aiding biotechnology entrepreneurs, and as an Advisory Board Member of the University of Colorado BioFrontiers Institute. Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.
- Michael Riebe
-
Michael Riebe自2016年12月以来一直担任我们的董事会成员。Shah先生目前担任RA Capital Management，LLC（一家投资咨询公司，投资于梦百合和生命科学公司）的投资组合经理兼董事总经理，他自2004年6月以来一直担任该职位。Shah先生目前是所有生命科学公司Kala制药有限公司、RaPharmaceuticals，Inc.、Solid Biosciences，Inc.和EidosTherapeutics，Inc.上市公司的董事会成员。Shah先生曾于2015年6月至2018年4月担任上市制药公司KalVistaPharmaceuticals，Inc.的董事会成员。Shah先生拥有康奈尔大学（Cornell University）化学学士学位。
Michael Riebe has served as a member of our board of directors since December 2016. Mr. Shah currently serves as Portfolio Manager & Managing Director at RA Capital Management, LLC, an investment advisory firm that invests in healthcare and life science companies, a position he has held since June 2004. Mr. Shah is currently a member of the board of directors of the public companies Kala Pharmaceuticals, Inc., Ra Pharmaceuticals, Inc., Solid Biosciences, Inc. and Eidos Therapeutics, Inc., all life sciences companies. Mr. Shah was previously a member of the board of directors of KalVista Pharmaceuticals, Inc., a public pharmaceutical company, from June 2015 through April 2018. Mr. Shah holds a B.A. in Chemistry from Cornell University. - Michael Riebe自2016年12月以来一直担任我们的董事会成员。Shah先生目前担任RA Capital Management，LLC（一家投资咨询公司，投资于梦百合和生命科学公司）的投资组合经理兼董事总经理，他自2004年6月以来一直担任该职位。Shah先生目前是所有生命科学公司Kala制药有限公司、RaPharmaceuticals，Inc.、Solid Biosciences，Inc.和EidosTherapeutics，Inc.上市公司的董事会成员。Shah先生曾于2015年6月至2018年4月担任上市制药公司KalVistaPharmaceuticals，Inc.的董事会成员。Shah先生拥有康奈尔大学（Cornell University）化学学士学位。
- Michael Riebe has served as a member of our board of directors since December 2016. Mr. Shah currently serves as Portfolio Manager & Managing Director at RA Capital Management, LLC, an investment advisory firm that invests in healthcare and life science companies, a position he has held since June 2004. Mr. Shah is currently a member of the board of directors of the public companies Kala Pharmaceuticals, Inc., Ra Pharmaceuticals, Inc., Solid Biosciences, Inc. and Eidos Therapeutics, Inc., all life sciences companies. Mr. Shah was previously a member of the board of directors of KalVista Pharmaceuticals, Inc., a public pharmaceutical company, from June 2015 through April 2018. Mr. Shah holds a B.A. in Chemistry from Cornell University.
- Elisabeth Sandoval Little
-
Elisabeth Sandoval Little，她曾担任Menlo Therapeutics Inc.的成员。自2019年3月起担任董事。她目前担任制药行业的顾问。从2016年9月到2019年4月，她担任Alder Biopharmaceuticals（一家上市生物制药公司）的首席商务官和企业战略执行副总裁，主要负责领导、开发和执行商业战略。她还负责开发和领导Alder的医疗事务、投资者关系、企业沟通和业务发展职能。在加入Alder之前，她曾担任Kythera Biopharmaceuticals（一家上市的生物制药公司）的首席商务官，在那里她领导商业战略和执行，直到Kythera被Allergan收购。在Kythera之前，Sandoval女士是Bausch and Lomb Surgical的营销副总裁。在此之前，她曾担任Allergan的全球营销副总裁。她还担任Alastin Skincare（一家私人控股公司）的董事会成员。Sandoval女士的职业生涯始于Johnson & Johnson的Ethicon部门的研究和开发。她持有Pepperdine大学的工商管理硕士学位和California大学， Irvine的生物学学士学位。
Elisabeth Sandoval Little has served on Board since March 2019. Ms. Sandoval Little currently serves as a consultant to the pharmaceutical indtry. From 2016 to 2019, she served as the Chief Commercial Officer and Executive Vice President of Corporate Strategy for Alder Biopharmaceuticals, a publicly held biopharmaceutical company. From 2012 to 2015, Ms. Sandoval Little was Chief Commercial Officer for KYTHERA Biopharmaceuticals until KYTHERA's acquisition by Allergan. Ms. Sandoval Little previoly served as Vice President of Marketing for Bach and Lomb Surgical and Vice President of Global Marketing at Allergan with responsibility for the Medical Aesthetics division. She spent over 20 years at Allergan in sales and marketing leadership roles in the specialties of dermatology, neurology, and aesthetics. Ms. Sandoval Little began her career in research and development at Johnson & Johnson's Ethicon division. Ms. Sandoval Little currently serves on the board of directors of the publicly held company PROCEPT BioRobotics Corporation and previoly served on the board of directors of the publicly held company Satsuma Pharmaceuticals from May 2019 until June 2023 and the publicly held company Intersect ENT, Inc. from April 2021 until its acquisition by Medtronic plc in May 2022. She holds an M.B.A. from Pepperdine University and a B.S. in biology from the University of California, Irvine. - Elisabeth Sandoval Little，她曾担任Menlo Therapeutics Inc.的成员。自2019年3月起担任董事。她目前担任制药行业的顾问。从2016年9月到2019年4月，她担任Alder Biopharmaceuticals（一家上市生物制药公司）的首席商务官和企业战略执行副总裁，主要负责领导、开发和执行商业战略。她还负责开发和领导Alder的医疗事务、投资者关系、企业沟通和业务发展职能。在加入Alder之前，她曾担任Kythera Biopharmaceuticals（一家上市的生物制药公司）的首席商务官，在那里她领导商业战略和执行，直到Kythera被Allergan收购。在Kythera之前，Sandoval女士是Bausch and Lomb Surgical的营销副总裁。在此之前，她曾担任Allergan的全球营销副总裁。她还担任Alastin Skincare（一家私人控股公司）的董事会成员。Sandoval女士的职业生涯始于Johnson & Johnson的Ethicon部门的研究和开发。她持有Pepperdine大学的工商管理硕士学位和California大学， Irvine的生物学学士学位。
- Elisabeth Sandoval Little has served on Board since March 2019. Ms. Sandoval Little currently serves as a consultant to the pharmaceutical indtry. From 2016 to 2019, she served as the Chief Commercial Officer and Executive Vice President of Corporate Strategy for Alder Biopharmaceuticals, a publicly held biopharmaceutical company. From 2012 to 2015, Ms. Sandoval Little was Chief Commercial Officer for KYTHERA Biopharmaceuticals until KYTHERA's acquisition by Allergan. Ms. Sandoval Little previoly served as Vice President of Marketing for Bach and Lomb Surgical and Vice President of Global Marketing at Allergan with responsibility for the Medical Aesthetics division. She spent over 20 years at Allergan in sales and marketing leadership roles in the specialties of dermatology, neurology, and aesthetics. Ms. Sandoval Little began her career in research and development at Johnson & Johnson's Ethicon division. Ms. Sandoval Little currently serves on the board of directors of the publicly held company PROCEPT BioRobotics Corporation and previoly served on the board of directors of the publicly held company Satsuma Pharmaceuticals from May 2019 until June 2023 and the publicly held company Intersect ENT, Inc. from April 2021 until its acquisition by Medtronic plc in May 2022. She holds an M.B.A. from Pepperdine University and a B.S. in biology from the University of California, Irvine.
- John A. Kollins
-
John A. Kollins。自2012年6月，Kollins先生担任公司高级副总裁兼首席商务官，此前，从2011年9月至2012年5月，Kollins先生是Parnassus Advisors的创立人及总经理，这是一个生命科学咨询公司，从2009年12月至2011年9月是生命科学咨询公司Locust Walk Partners的总经理兼高级顾问，2007年3月至2009年10月，他先后担任 OXiGENE首席商务官，首席运营官兼首席执行官，这是一个公开上市的生物制药公司。从2005年至2007 Kollins先生是医疗投资公司和生命科学公司的顾问。 Kollins先生也曾在不同的生物制药公司，包括CovX，Renovis和Elan制药公司担任主管，业务开发和产品管理的角色。 Kollins先生持有杜克大学（ Duke University）机械工程学士学位和弗吉尼亚大学（University of Virginia）材料科学管理硕士学位。
John A. Kollins has served as a member of our board of directors and as our President and Chief Executive Officer since July 2016. Since 1989 Mr. Kollins has worked in the biopharmaceutical industry in Director, CEO, executive management, business and corporate development, and commercial roles. He has served in CNS-focused biopharmaceutical companies, including Transcept Pharmaceuticals, where he served from June 2012 to October 2014 as Chief Business Officer, Renovis, Elan Pharmaceuticals and Athena Neurosciences. From November 2014 until co-founding Satsuma Pharmaceuticals in July 2016 Mr. Kollins was Managing Director of Parnassus Advisors, LLC, which he founded to provide strategic consulting and corporate development services to biopharmaceutical companies. Mr. Kollins earned an M.B.A. from the University of Virginia’s Darden School and an engineering degree from Duke University. - John A. Kollins。自2012年6月，Kollins先生担任公司高级副总裁兼首席商务官，此前，从2011年9月至2012年5月，Kollins先生是Parnassus Advisors的创立人及总经理，这是一个生命科学咨询公司，从2009年12月至2011年9月是生命科学咨询公司Locust Walk Partners的总经理兼高级顾问，2007年3月至2009年10月，他先后担任 OXiGENE首席商务官，首席运营官兼首席执行官，这是一个公开上市的生物制药公司。从2005年至2007 Kollins先生是医疗投资公司和生命科学公司的顾问。 Kollins先生也曾在不同的生物制药公司，包括CovX，Renovis和Elan制药公司担任主管，业务开发和产品管理的角色。 Kollins先生持有杜克大学（ Duke University）机械工程学士学位和弗吉尼亚大学（University of Virginia）材料科学管理硕士学位。
- John A. Kollins has served as a member of our board of directors and as our President and Chief Executive Officer since July 2016. Since 1989 Mr. Kollins has worked in the biopharmaceutical industry in Director, CEO, executive management, business and corporate development, and commercial roles. He has served in CNS-focused biopharmaceutical companies, including Transcept Pharmaceuticals, where he served from June 2012 to October 2014 as Chief Business Officer, Renovis, Elan Pharmaceuticals and Athena Neurosciences. From November 2014 until co-founding Satsuma Pharmaceuticals in July 2016 Mr. Kollins was Managing Director of Parnassus Advisors, LLC, which he founded to provide strategic consulting and corporate development services to biopharmaceutical companies. Mr. Kollins earned an M.B.A. from the University of Virginia’s Darden School and an engineering degree from Duke University.
- Heath Lukatch
-
Heath Lukatch，他一直担任Bicara Therapeutics公司的董事会成员（2013年8月以来）。自2020年3月以来，Lukatch博士一直担任Red Tree Venture Capital（私人持有的生命科学风险投资公司）的创始人和管理合伙人。在创立Red Tree Venture Capital之前，从2015年5月到2020年3月，Lukatch博士在TPG工作，担任TPG的Biotech、Growth和RISE平台的合伙人、董事总经理和生命科学投资团队负责人。2006年4月，Lukatch博士共同创立了Novo Ventures （US） Inc.的旧金山办事处，这是一家风险投资公司，他在那里担任合伙人至2015年4月。Lukatch博士目前是生物技术公司Vaxcyte, Inc.（纳斯达克股票代码：PCVX）的董事会成员，自2018年5月以来，他还担任多家私营公司的董事会成员。此前，Lukatch博士于2021年1月至2023年11月担任生物技术公司Cargo Therapeutics, Inc.（纳斯达克股票代码：CRGX）的董事会成员，2016年12月至2023年6月担任制药公司Satsuma Pharmaceuticals, Inc.（纳斯达克股票代码：STSA）的董事会成员，2006年12月至2022年3月担任医疗技术公司Inogen, Inc.（纳斯达克股票代码：INGN）的董事会成员，以及Flexion Therapeutics, Inc.(纳斯达克股票代码：从2012年12月到2021年11月，该公司被Pacira BioSciences, Inc.和其他几家私人公司收购。Lukatch博士在斯坦福大学获得神经科学博士学位，在加州大学伯克利分校获得生物化学学士学位。
Heath Lukatch,has served as a member of Bicara Therapeutics Inc. board of directors since August 2023. Since March 2020, Dr. Lukatch has served as Founder and Managing Partner of Red Tree Venture Capital, a privately held life sciences venture capital firm. Prior to founding Red Tree Venture Capital, from May 2015 to March 2020, Dr. Lukatch worked at TPG, where he was Partner, Managing Director and Life Sciences Investment Team Leader in TPG's Biotech, Growth and RISE platforms. In April 2006, Dr. Lukatch co-founded Novo Ventures (US) Inc.'s San Francisco office, a venture capital firm, where he was a Partner through April 2015. Dr. Lukatch is currently a member of the board of directors Vaxcyte, Inc. (NASDAQ: PCVX), a biotechnology company, since May 2018 and also serves on the boards of directors of various private companies. Previously, Dr. Lukatch served on the board of Cargo Therapeutics, Inc. (NASDAQ: CRGX), a biotechnology company, from January 2021 to November 2023, Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA), a pharmaceutical company, from December 2016 to June 2023, Inogen, Inc. (NASDAQ: INGN), a medical technology company, from December 2006 to March 2022, and Flexion Therapeutics, Inc. (NASDAQ: FLXN), a biopharmaceutical company from December 2012 to November 2021, when it was acquired by Pacira BioSciences, Inc., and several other private companies. Dr. Lukatch received his Ph.D. in Neuroscience from Stanford University and his B.A. in Biochemistry from the University of California at Berkeley. - Heath Lukatch，他一直担任Bicara Therapeutics公司的董事会成员（2013年8月以来）。自2020年3月以来，Lukatch博士一直担任Red Tree Venture Capital（私人持有的生命科学风险投资公司）的创始人和管理合伙人。在创立Red Tree Venture Capital之前，从2015年5月到2020年3月，Lukatch博士在TPG工作，担任TPG的Biotech、Growth和RISE平台的合伙人、董事总经理和生命科学投资团队负责人。2006年4月，Lukatch博士共同创立了Novo Ventures （US） Inc.的旧金山办事处，这是一家风险投资公司，他在那里担任合伙人至2015年4月。Lukatch博士目前是生物技术公司Vaxcyte, Inc.（纳斯达克股票代码：PCVX）的董事会成员，自2018年5月以来，他还担任多家私营公司的董事会成员。此前，Lukatch博士于2021年1月至2023年11月担任生物技术公司Cargo Therapeutics, Inc.（纳斯达克股票代码：CRGX）的董事会成员，2016年12月至2023年6月担任制药公司Satsuma Pharmaceuticals, Inc.（纳斯达克股票代码：STSA）的董事会成员，2006年12月至2022年3月担任医疗技术公司Inogen, Inc.（纳斯达克股票代码：INGN）的董事会成员，以及Flexion Therapeutics, Inc.(纳斯达克股票代码：从2012年12月到2021年11月，该公司被Pacira BioSciences, Inc.和其他几家私人公司收购。Lukatch博士在斯坦福大学获得神经科学博士学位，在加州大学伯克利分校获得生物化学学士学位。
- Heath Lukatch,has served as a member of Bicara Therapeutics Inc. board of directors since August 2023. Since March 2020, Dr. Lukatch has served as Founder and Managing Partner of Red Tree Venture Capital, a privately held life sciences venture capital firm. Prior to founding Red Tree Venture Capital, from May 2015 to March 2020, Dr. Lukatch worked at TPG, where he was Partner, Managing Director and Life Sciences Investment Team Leader in TPG's Biotech, Growth and RISE platforms. In April 2006, Dr. Lukatch co-founded Novo Ventures (US) Inc.'s San Francisco office, a venture capital firm, where he was a Partner through April 2015. Dr. Lukatch is currently a member of the board of directors Vaxcyte, Inc. (NASDAQ: PCVX), a biotechnology company, since May 2018 and also serves on the boards of directors of various private companies. Previously, Dr. Lukatch served on the board of Cargo Therapeutics, Inc. (NASDAQ: CRGX), a biotechnology company, from January 2021 to November 2023, Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA), a pharmaceutical company, from December 2016 to June 2023, Inogen, Inc. (NASDAQ: INGN), a medical technology company, from December 2006 to March 2022, and Flexion Therapeutics, Inc. (NASDAQ: FLXN), a biopharmaceutical company from December 2012 to November 2021, when it was acquired by Pacira BioSciences, Inc., and several other private companies. Dr. Lukatch received his Ph.D. in Neuroscience from Stanford University and his B.A. in Biochemistry from the University of California at Berkeley.
高管简历
中英对照 | 中文 | 英文- Detlef Albrecht
Detlef Albrecht自2017年7月起担任首席医疗官。此前，Albrecht博士曾于2015年5月至2017年6月在制药公司Armetheon，Inc.担任多个职位，最近担任研究与开发主管。他也曾担任Sorbent Therapeutics公司（生物制药公司）的总裁兼首席执行官（从2010年8月到2014年7月）。Albrecht博士在莱茵西大学（Rheinisch-Westf&228；Lische Technische Hochschule Aachen University）获得博士学位和医学博士学位。
Detlef Albrecht has served as our Chief Medical Officer since July 2017. Previously, Dr. Albrecht served in various roles at Armetheon, Inc., a pharmaceutical company, from May 2015 to June 2017 most recently as Head of Research and Development. He also served as President and Chief Executive Officer for Sorbent Therapeutics, Inc., a biopharmaceutical company, from August 2010 to July 2014. Dr. Albrecht received a Physician Degree and an M.D. from Rheinisch-Westfälische Technische Hochschule Aachen University.- Detlef Albrecht自2017年7月起担任首席医疗官。此前，Albrecht博士曾于2015年5月至2017年6月在制药公司Armetheon，Inc.担任多个职位，最近担任研究与开发主管。他也曾担任Sorbent Therapeutics公司（生物制药公司）的总裁兼首席执行官（从2010年8月到2014年7月）。Albrecht博士在莱茵西大学（Rheinisch-Westf&228；Lische Technische Hochschule Aachen University）获得博士学位和医学博士学位。
- Detlef Albrecht has served as our Chief Medical Officer since July 2017. Previously, Dr. Albrecht served in various roles at Armetheon, Inc., a pharmaceutical company, from May 2015 to June 2017 most recently as Head of Research and Development. He also served as President and Chief Executive Officer for Sorbent Therapeutics, Inc., a biopharmaceutical company, from August 2010 to July 2014. Dr. Albrecht received a Physician Degree and an M.D. from Rheinisch-Westfälische Technische Hochschule Aachen University.
- Tom O'Neil
TomO’Neil自2019年1月起担任我们的首席财务官。此前，奥尼尔曾于2016年2月至2019年1月担任上市生物制药公司ProtagonistTherapeutics，Inc.的首席财务官。在此之前，他曾于2015年3月至2015年9月担任生物制药公司阿凯迪亚生物科学公司的首席财务官。2014年1月至2014年7月，奥尼尔先生担任生物制药公司Sorbent Therapeutics，Inc.的首席财务官。从2011年9月至2013年12月，O’Neil先生担任Sorbent和各种医疗保健和技术公司的顾问。2009年12月至2011年8月，奥尼尔先生担任生物制药公司Chemgenex Pharmaceuticals Ltd.的财务与管理Vice President。2007年3月至2009年5月，奥尼尔先生担任生物技术公司Nodality，Inc.的财务与管理Vice President。O’Neil先生在波莫纳学院（Pomona College）获得国际关系学士学位，并在加州大学洛杉矶分校安德森管理研究生院（UCLA Anderson Graduate School of Management）获得工商管理硕士学位。
Tom O'Neil has served as our Chief Financial Officer since January 2019. Previously, Mr. O'Neil served as Chief Financial Officer at Protagonist Therapeutics, Inc., a public biopharmaceutical company, from February 2016 to January 2019. Prior to that, he served as Chief Financial Officer for Arcadia Biosciences, Inc., a biopharmaceutical company, from March 2015 to September 2015. From January 2014 to July 2014 Mr. O'Neil served as Chief Financial Officer of Sorbent Therapeutics, Inc., a biopharmaceutical company. From September 2011 to December 2013 Mr. O'Neil served as a consultant to Sorbent and a variety of health care and technology companies. From December 2009 to August 2011 Mr. O'Neil served as Vice President of Finance & Administration of ChemGenex Pharmaceuticals Ltd., a biopharmaceutical company. From March 2007 to May 2009 Mr. O'Neil served as Vice President of Finance & Administration of Nodality, Inc., a biotechnology company. Mr. O'Neil received a BA in International Relations from Pomona College, and an M.B.A. from The UCLA Anderson Graduate School of Management.- TomO’Neil自2019年1月起担任我们的首席财务官。此前，奥尼尔曾于2016年2月至2019年1月担任上市生物制药公司ProtagonistTherapeutics，Inc.的首席财务官。在此之前，他曾于2015年3月至2015年9月担任生物制药公司阿凯迪亚生物科学公司的首席财务官。2014年1月至2014年7月，奥尼尔先生担任生物制药公司Sorbent Therapeutics，Inc.的首席财务官。从2011年9月至2013年12月，O’Neil先生担任Sorbent和各种医疗保健和技术公司的顾问。2009年12月至2011年8月，奥尼尔先生担任生物制药公司Chemgenex Pharmaceuticals Ltd.的财务与管理Vice President。2007年3月至2009年5月，奥尼尔先生担任生物技术公司Nodality，Inc.的财务与管理Vice President。O’Neil先生在波莫纳学院（Pomona College）获得国际关系学士学位，并在加州大学洛杉矶分校安德森管理研究生院（UCLA Anderson Graduate School of Management）获得工商管理硕士学位。
- Tom O'Neil has served as our Chief Financial Officer since January 2019. Previously, Mr. O'Neil served as Chief Financial Officer at Protagonist Therapeutics, Inc., a public biopharmaceutical company, from February 2016 to January 2019. Prior to that, he served as Chief Financial Officer for Arcadia Biosciences, Inc., a biopharmaceutical company, from March 2015 to September 2015. From January 2014 to July 2014 Mr. O'Neil served as Chief Financial Officer of Sorbent Therapeutics, Inc., a biopharmaceutical company. From September 2011 to December 2013 Mr. O'Neil served as a consultant to Sorbent and a variety of health care and technology companies. From December 2009 to August 2011 Mr. O'Neil served as Vice President of Finance & Administration of ChemGenex Pharmaceuticals Ltd., a biopharmaceutical company. From March 2007 to May 2009 Mr. O'Neil served as Vice President of Finance & Administration of Nodality, Inc., a biotechnology company. Mr. O'Neil received a BA in International Relations from Pomona College, and an M.B.A. from The UCLA Anderson Graduate School of Management.
- Mic Iwashima
Mic Iwashima自2017年1月起担任我们的Vice President兼运营主管。在此之前，岩岛先生于2002年6月至2017年3月受雇于新日生物医学实验室有限公司（Shin Nippon Biomedical Laboratories，Ltd.），最近担任研发全球主管。Iwashima先生在北卡罗来纳州立大学（North Carolina State University）获得机械工程学士学位。
Mic Iwashima has served as our Vice President and Head of Operations since January 2017. Prior to that, Mr. Iwashima was employed by Shin Nippon Biomedical Laboratories, Ltd. from June 2002 to March 2017 most recently as Global Head of R&D. Mr. Iwashima received a B.S. in Mechanical Engineering from North Carolina State University.- Mic Iwashima自2017年1月起担任我们的Vice President兼运营主管。在此之前，岩岛先生于2002年6月至2017年3月受雇于新日生物医学实验室有限公司（Shin Nippon Biomedical Laboratories，Ltd.），最近担任研发全球主管。Iwashima先生在北卡罗来纳州立大学（North Carolina State University）获得机械工程学士学位。
- Mic Iwashima has served as our Vice President and Head of Operations since January 2017. Prior to that, Mr. Iwashima was employed by Shin Nippon Biomedical Laboratories, Ltd. from June 2002 to March 2017 most recently as Global Head of R&D. Mr. Iwashima received a B.S. in Mechanical Engineering from North Carolina State University.
- Robert Schultz
Robert Schultz自2017年7月起担任我们的Vice President兼CMC负责人。在此之前，Schultz先生于2007年8月至2019年7月受雇于Pearl Therapeutics，最近担任高级总监。2004年7月至2007年8月，他还担任KOS Pharmaceuticals的副董事。Schultz先生在达特茅斯学院（Dartmouth College）获得生物化学学士学位。
Robert Schultz has served as our Vice President and Head of CMC since July 2017. Prior to that, Mr. Schultz was employed by Pearl Therapeutics from August 2007 to July 2019 most recently as Senior Director. He has also served as Associate Director for Kos Pharmaceuticals from July 2004 to August 2007. Mr. Schultz received a B.A. in Biochemistry from Dartmouth College.- Robert Schultz自2017年7月起担任我们的Vice President兼CMC负责人。在此之前，Schultz先生于2007年8月至2019年7月受雇于Pearl Therapeutics，最近担任高级总监。2004年7月至2007年8月，他还担任KOS Pharmaceuticals的副董事。Schultz先生在达特茅斯学院（Dartmouth College）获得生物化学学士学位。
- Robert Schultz has served as our Vice President and Head of CMC since July 2017. Prior to that, Mr. Schultz was employed by Pearl Therapeutics from August 2007 to July 2019 most recently as Senior Director. He has also served as Associate Director for Kos Pharmaceuticals from July 2004 to August 2007. Mr. Schultz received a B.A. in Biochemistry from Dartmouth College.
- Shannon Strom
Shannon Strom自2018年5月起担任我们的Vice President兼监管事务主管。在此之前，Strom博士于2018年1月至2018年5月受聘于Roivant Sciences，最近担任全球监管事务高级总监。她于2010年1月至2018年1月受聘于阿斯利康的全资子公司Pearl Therapeutics，最近担任法规事务高级总监。Strom博士在杜克大学（Duke University）获得生物学学士学位，并在北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）获得药理学博士学位。
Shannon Strom has served as our Vice President and Head of Regulatory Affairs since May 2018. Prior to that, Dr. Strom was employed by Roivant Sciences from January 2018 to May 2018 most recently as Senior Director, Global Regulatory Affairs. She was employed by Pearl Therapeutics, a wholly-owned subsidiary of AstraZeneca, from January 2010 to January 2018 most recently as Senior Director for Regulatory Affairs. Dr. Strom received a B.S. in Biology from Duke University, and a Ph.D. in Pharmacology from the University of North Carolina at Chapel Hill.- Shannon Strom自2018年5月起担任我们的Vice President兼监管事务主管。在此之前，Strom博士于2018年1月至2018年5月受聘于Roivant Sciences，最近担任全球监管事务高级总监。她于2010年1月至2018年1月受聘于阿斯利康的全资子公司Pearl Therapeutics，最近担任法规事务高级总监。Strom博士在杜克大学（Duke University）获得生物学学士学位，并在北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）获得药理学博士学位。
- Shannon Strom has served as our Vice President and Head of Regulatory Affairs since May 2018. Prior to that, Dr. Strom was employed by Roivant Sciences from January 2018 to May 2018 most recently as Senior Director, Global Regulatory Affairs. She was employed by Pearl Therapeutics, a wholly-owned subsidiary of AstraZeneca, from January 2010 to January 2018 most recently as Senior Director for Regulatory Affairs. Dr. Strom received a B.S. in Biology from Duke University, and a Ph.D. in Pharmacology from the University of North Carolina at Chapel Hill.
- John A. Kollins
John A. Kollins。自2012年6月，Kollins先生担任公司高级副总裁兼首席商务官，此前，从2011年9月至2012年5月，Kollins先生是Parnassus Advisors的创立人及总经理，这是一个生命科学咨询公司，从2009年12月至2011年9月是生命科学咨询公司Locust Walk Partners的总经理兼高级顾问，2007年3月至2009年10月，他先后担任 OXiGENE首席商务官，首席运营官兼首席执行官，这是一个公开上市的生物制药公司。从2005年至2007 Kollins先生是医疗投资公司和生命科学公司的顾问。 Kollins先生也曾在不同的生物制药公司，包括CovX，Renovis和Elan制药公司担任主管，业务开发和产品管理的角色。 Kollins先生持有杜克大学（ Duke University）机械工程学士学位和弗吉尼亚大学（University of Virginia）材料科学管理硕士学位。
John A. Kollins has served as a member of our board of directors and as our President and Chief Executive Officer since July 2016. Since 1989 Mr. Kollins has worked in the biopharmaceutical industry in Director, CEO, executive management, business and corporate development, and commercial roles. He has served in CNS-focused biopharmaceutical companies, including Transcept Pharmaceuticals, where he served from June 2012 to October 2014 as Chief Business Officer, Renovis, Elan Pharmaceuticals and Athena Neurosciences. From November 2014 until co-founding Satsuma Pharmaceuticals in July 2016 Mr. Kollins was Managing Director of Parnassus Advisors, LLC, which he founded to provide strategic consulting and corporate development services to biopharmaceutical companies. Mr. Kollins earned an M.B.A. from the University of Virginia’s Darden School and an engineering degree from Duke University.- John A. Kollins。自2012年6月，Kollins先生担任公司高级副总裁兼首席商务官，此前，从2011年9月至2012年5月，Kollins先生是Parnassus Advisors的创立人及总经理，这是一个生命科学咨询公司，从2009年12月至2011年9月是生命科学咨询公司Locust Walk Partners的总经理兼高级顾问，2007年3月至2009年10月，他先后担任 OXiGENE首席商务官，首席运营官兼首席执行官，这是一个公开上市的生物制药公司。从2005年至2007 Kollins先生是医疗投资公司和生命科学公司的顾问。 Kollins先生也曾在不同的生物制药公司，包括CovX，Renovis和Elan制药公司担任主管，业务开发和产品管理的角色。 Kollins先生持有杜克大学（ Duke University）机械工程学士学位和弗吉尼亚大学（University of Virginia）材料科学管理硕士学位。
- John A. Kollins has served as a member of our board of directors and as our President and Chief Executive Officer since July 2016. Since 1989 Mr. Kollins has worked in the biopharmaceutical industry in Director, CEO, executive management, business and corporate development, and commercial roles. He has served in CNS-focused biopharmaceutical companies, including Transcept Pharmaceuticals, where he served from June 2012 to October 2014 as Chief Business Officer, Renovis, Elan Pharmaceuticals and Athena Neurosciences. From November 2014 until co-founding Satsuma Pharmaceuticals in July 2016 Mr. Kollins was Managing Director of Parnassus Advisors, LLC, which he founded to provide strategic consulting and corporate development services to biopharmaceutical companies. Mr. Kollins earned an M.B.A. from the University of Virginia’s Darden School and an engineering degree from Duke University.